Holen Sie sich die Stockscreener-App
84.01
0.39%
-0.33
Handel nachbörslich:
84.01
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 By Investing.com - Investing.com Canada
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 - Investing.com
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Apogee Therapeutics (APGE) CMO trades 5,500 shares under 10b5-1 plan - Stock Titan
Responsive Playbooks and the APGE Inflection - Stock Traders Daily
APGE Technical Analysis & Stock Price Forecast - Intellectia AI
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN
Banque Pictet & Cie SA Invests $3.16 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Deutsche Bank Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $118 - Moomoo
SG Americas Securities LLC Sells 60,964 Shares of Apogee Therapeutics Inc. $APGE - marketbeat.com
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's What Happened - MarketBeat
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137 - Moomoo
APGE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Market Rankings: Will Apogee Therapeutics Inc benefit from seasonalityEarnings Recap Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target By Investing.com - za.investing.com
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - MarketBeat
Mizuho raises Apogee Therapeutics stock price target on AD data By Investing.com - za.investing.com
Mizuho raises Apogee Therapeutics stock price target on AD data - Investing.com
Mizuho Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110 - Moomoo
Apogee Therapeutics announces $300 million public offering - MSN
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics (APGE) price target increased by 11.74% to 118.86 - MSN
Wolfe Research initiates coverage of Apogee Therapeutics (APGE) with peer perform recommendation - MSN
Insider Sell Alert: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CFO Henderson sells $170k in stock By Investing.com - Investing.com Australia
Apogee Therapeutics CFO Henderson sells $170k in stock - Investing.com
Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data - finance.yahoo.com
Apogee Therapeutics (APGE) CFO sells 2,000 shares in planned trade - Stock Titan
Fairmount Funds reveals near-10% Apogee Therapeutics (APGE) stake and 60-day lock-up - Stock Titan
Apogee Therapeutics raises $403 million in stock offering By Investing.com - au.investing.com
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):